Our top pick for
AtriCure Inc is a medical instruments & supplies business based in the US. AtriCure shares (ATRC) are listed on the NASDAQ and all prices are listed in US Dollars. AtriCure employs 750 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$71.37|
|52-week range||$34.04 - $85.50|
|50-day moving average||$72.98|
|200-day moving average||$74.35|
|Wall St. target price||$96.71|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.28|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||0.69%|
|1 month (2021-09-17)||-6.96%|
|3 months (2021-07-16)||-8.00%|
|6 months (2021-04-16)||4.96%|
|1 year (2020-10-16)||75.40%|
|2 years (2019-10-16)||167.86%|
|3 years (2018-10-16)||126.07%|
|5 years (2016-10-14)||330.20%|
|Revenue TTM||$243.1 million|
|Gross profit TTM||$149.3 million|
|Return on assets TTM||-3.25%|
|Return on equity TTM||-14.14%|
|Market capitalisation||$3.3 billion|
TTM: trailing 12 months
There are currently 1.0 million AtriCure shares held short by investors – that's known as AtriCure's "short interest". This figure is 10.9% up from 929,409 last month.
There are a few different ways that this level of interest in shorting AtriCure shares can be evaluated.
AtriCure's "short interest ratio" (SIR) is the quantity of AtriCure shares currently shorted divided by the average quantity of AtriCure shares traded daily (recently around 193816.54135338). AtriCure's SIR currently stands at 5.32. In other words for every 100,000 AtriCure shares traded daily on the market, roughly 5320 shares are currently held short.
However AtriCure's short interest can also be evaluated against the total number of AtriCure shares, or, against the total number of tradable AtriCure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AtriCure's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 AtriCure shares in existence, roughly 20 shares are currently held short) or 0.0231% of the tradable shares (for every 100,000 tradable AtriCure shares, roughly 23 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against AtriCure.
Find out more about how you can short AtriCure stock.
We're not expecting AtriCure to pay a dividend over the next 12 months.
Over the last 12 months, AtriCure's shares have ranged in value from as little as $34.04 up to $85.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AtriCure's is 1.0571. This would suggest that AtriCure's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.